Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Garsorasib - Inventis Bio

Next Previous
Drug Profile

Garsorasib - Inventis Bio

Alternative Names: Anfangning; D-1553

Latest Information Update: 12 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator InventisBio
  • Developer Chia Tai Tianqing Pharmaceutical Group; InventisBio
  • Class 2 ring heterocyclic compounds; Acrylates; Aniline compounds; Antineoplastics; Benzene derivatives; Cyclopropanes; Fluorinated hydrocarbons; Fluorobenzenes; Piperazines; Pyridines; Pyrimidines; Pyrimidinones; Small molecules
  • Mechanism of Action KRAS protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Non-small cell lung cancer
  • Phase I/II Colorectal cancer; Solid tumours

Most Recent Events

  • 06 Jan 2026 Suzhou Genhouse Bio plans a phase II trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO, Capsule) December 2025 (NCT07318649)
  • 23 Dec 2025 Chia Tai Tianqing Pharmaceutical Group plans a phase II trial for Non-small cell lung cancer (Late-stage disease, metastatic disease, First-line therapy, Combination therapy) in China (PO) in December 2025 (NCT07294261)
  • 16 Sep 2025 InxMed plans a phase III trial for Non-small cell lung cancer (Late-stage disease, Metastatic disease, First-line therapy, Combination therapy) in unknown location (PO) in September 2025(NCT07174908)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top